EP3569592A4 - Hdac6 selective inhibitors, preparation method therefor, and application thereof - Google Patents
Hdac6 selective inhibitors, preparation method therefor, and application thereof Download PDFInfo
- Publication number
- EP3569592A4 EP3569592A4 EP18739134.7A EP18739134A EP3569592A4 EP 3569592 A4 EP3569592 A4 EP 3569592A4 EP 18739134 A EP18739134 A EP 18739134A EP 3569592 A4 EP3569592 A4 EP 3569592A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- application
- method therefor
- selective inhibitors
- hdac6 selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710017287 | 2017-01-10 | ||
| PCT/CN2018/072088 WO2018130155A1 (en) | 2017-01-10 | 2018-01-10 | Hdac6 selective inhibitors, preparation method therefor, and application thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP3569592A1 EP3569592A1 (en) | 2019-11-20 |
| EP3569592A4 true EP3569592A4 (en) | 2020-08-12 |
| EP3569592B1 EP3569592B1 (en) | 2022-08-24 |
| EP3569592B8 EP3569592B8 (en) | 2022-11-30 |
Family
ID=62839715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18739134.7A Active EP3569592B8 (en) | 2017-01-10 | 2018-01-10 | Hdac6 selective inhibitors, preparation method therefor, and application thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10745389B2 (en) |
| EP (1) | EP3569592B8 (en) |
| JP (1) | JP7237010B2 (en) |
| KR (1) | KR102549606B1 (en) |
| CN (1) | CN110382463B (en) |
| AU (1) | AU2018208160B2 (en) |
| BR (1) | BR112019014152A2 (en) |
| CA (1) | CA3049834A1 (en) |
| ES (1) | ES2927352T3 (en) |
| IL (1) | IL267968B (en) |
| MX (1) | MX2019008181A (en) |
| SA (1) | SA519402090B1 (en) |
| SG (1) | SG11201906361YA (en) |
| WO (1) | WO2018130155A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961765T3 (en) | 2018-07-04 | 2024-03-13 | Cstone Pharmaceuticals Suzhou Co Ltd | HDAC6 selective inhibitor polymorph and its application |
| WO2021110121A1 (en) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Hdac6 selective inhibitor and combination therapy thereof |
| KR20240013098A (en) | 2021-04-23 | 2024-01-30 | 테나야 테라퓨틱스, 인코포레이티드 | HDAC6 inhibitors for use in the treatment of dilated cardiomyopathy |
| KR20240016950A (en) | 2021-05-04 | 2024-02-06 | 테나야 테라퓨틱스, 인코포레이티드 | 2-Fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazole, an HDAC6 inhibitor, for use in the treatment of metabolic diseases and HFPEF |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068109A2 (en) * | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2012098132A1 (en) * | 2011-01-21 | 2012-07-26 | F. Hoffmann-La Roche Ag | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer |
| WO2015007870A1 (en) * | 2013-07-18 | 2015-01-22 | Institut De Recherche Pour Le Developpement (I.R.D.) | New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof |
| US20150239869A1 (en) * | 2014-02-26 | 2015-08-27 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as hdac6 selective inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066579A2 (en) * | 2002-02-07 | 2003-08-14 | Axys Pharmaceuticals | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| CN101641338A (en) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | Multi-functional small molecules as anti-proliferative agents |
| CA2731323A1 (en) | 2008-07-28 | 2010-02-04 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| US20110212969A1 (en) | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US9890136B2 (en) * | 2013-12-23 | 2018-02-13 | The Trustees Of Columbia University In The City Of New York Memorial Sloan-Kettering Cancer Center | Selective HDAC6 inhibitors |
-
2018
- 2018-01-10 WO PCT/CN2018/072088 patent/WO2018130155A1/en unknown
- 2018-01-10 CN CN201880006463.5A patent/CN110382463B/en active Active
- 2018-01-10 AU AU2018208160A patent/AU2018208160B2/en active Active
- 2018-01-10 ES ES18739134T patent/ES2927352T3/en active Active
- 2018-01-10 BR BR112019014152-9A patent/BR112019014152A2/en active IP Right Grant
- 2018-01-10 MX MX2019008181A patent/MX2019008181A/en unknown
- 2018-01-10 JP JP2019557669A patent/JP7237010B2/en active Active
- 2018-01-10 EP EP18739134.7A patent/EP3569592B8/en active Active
- 2018-01-10 CA CA3049834A patent/CA3049834A1/en active Pending
- 2018-01-10 US US16/476,660 patent/US10745389B2/en active Active
- 2018-01-10 SG SG11201906361YA patent/SG11201906361YA/en unknown
- 2018-01-10 KR KR1020197022672A patent/KR102549606B1/en active IP Right Grant
-
2019
- 2019-07-09 SA SA519402090A patent/SA519402090B1/en unknown
- 2019-07-10 IL IL267968A patent/IL267968B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068109A2 (en) * | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2012098132A1 (en) * | 2011-01-21 | 2012-07-26 | F. Hoffmann-La Roche Ag | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer |
| WO2015007870A1 (en) * | 2013-07-18 | 2015-01-22 | Institut De Recherche Pour Le Developpement (I.R.D.) | New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof |
| US20150239869A1 (en) * | 2014-02-26 | 2015-08-27 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as hdac6 selective inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2018130155A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SA519402090B1 (en) | 2022-05-30 |
| RU2019124962A3 (en) | 2021-05-11 |
| IL267968A (en) | 2019-10-31 |
| RU2019124962A (en) | 2021-02-15 |
| CN110382463B (en) | 2022-11-04 |
| ES2927352T8 (en) | 2022-11-18 |
| US10745389B2 (en) | 2020-08-18 |
| EP3569592A1 (en) | 2019-11-20 |
| CN110382463A (en) | 2019-10-25 |
| WO2018130155A1 (en) | 2018-07-19 |
| ES2927352T3 (en) | 2022-11-04 |
| CA3049834A1 (en) | 2018-07-19 |
| KR102549606B1 (en) | 2023-06-29 |
| EP3569592B8 (en) | 2022-11-30 |
| IL267968B (en) | 2022-06-01 |
| BR112019014152A2 (en) | 2020-03-31 |
| JP2020505440A (en) | 2020-02-20 |
| SG11201906361YA (en) | 2019-08-27 |
| MX2019008181A (en) | 2019-12-09 |
| AU2018208160A1 (en) | 2019-08-15 |
| EP3569592B1 (en) | 2022-08-24 |
| US20190375735A1 (en) | 2019-12-12 |
| AU2018208160B2 (en) | 2021-03-04 |
| JP7237010B2 (en) | 2023-03-10 |
| KR20190103286A (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3733715A4 (en) | Triabody, preparation method and use thereof | |
| EP4042881A4 (en) | Microcapsule, preparation method and application thereof | |
| EP3484184A4 (en) | Acoustic field formation device, method, and program | |
| EP3401864A4 (en) | Method for selecting transaction application, and terminal | |
| EP3636646A4 (en) | Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof | |
| EP3632907A4 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| EP3324325A4 (en) | Method, client, and system for testing application | |
| EP3495354A4 (en) | Ido1 inhibitor and preparation method and application thereof | |
| IL278036A (en) | Hpk1 inhibitors, preparation method and application thereof | |
| EP3246327A4 (en) | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | |
| EP3251698A4 (en) | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof | |
| EP3572404A4 (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| EP3484177A4 (en) | Acoustic field formation device, method, and program | |
| EP3556769A4 (en) | Polymyxin derivative, preparation method and application thereof | |
| EP3627322A4 (en) | Application interaction method, interaction method and device | |
| IL267968B (en) | Hdac6 selective inhibitors, preparation method thereof, and application thereof | |
| EP3589670A4 (en) | Elastomer, method for preparation thereof, and use thereof | |
| EP3395366A4 (en) | Drug design method, obtained drug and application thereof | |
| EP3395292A4 (en) | Three-dimensional-measurement method, and three-dimensional-measurement device | |
| EP3547121A4 (en) | Combining device, combining method and combining program | |
| EP3637251A4 (en) | Method, device and terminal for executing hotpatch | |
| EP3504978A4 (en) | Lactase-containing double microcapsule, preparation method therefor, and use thereof | |
| EP3395835A4 (en) | Antibody having enhanced activity, and method for modifying same | |
| EP3858833A4 (en) | Aminonordecane derivative, and preparation method therefor and application thereof | |
| EP3480283A4 (en) | Slipperiness-imparting agent and slipperiness-imparting method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190809 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602018039711 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0211860000 Ipc: C07D0405040000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20200714 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/513 20060101ALI20200708BHEP Ipc: A61K 31/34 20060101ALI20200708BHEP Ipc: C07D 405/14 20060101ALI20200708BHEP Ipc: A61K 31/04 20060101ALI20200708BHEP Ipc: A61K 31/435 20060101ALI20200708BHEP Ipc: C07D 307/16 20060101ALI20200708BHEP Ipc: C07D 405/04 20060101AFI20200708BHEP Ipc: A61K 31/16 20060101ALI20200708BHEP Ipc: A61P 35/00 20060101ALI20200708BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210707 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20220309 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1513590 Country of ref document: AT Kind code of ref document: T Effective date: 20220915 Ref country code: DE Ref legal event code: R096 Ref document number: 602018039711 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2927352 Country of ref document: ES Kind code of ref document: T3 Effective date: 20221104 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNGEN Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
| RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: CSTONE PHARMACEUTICALS Owner name: CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. Owner name: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220824 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221226 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221124 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1513590 Country of ref document: AT Kind code of ref document: T Effective date: 20220824 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221224 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221125 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018039711 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20230525 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230110 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231226 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230110 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231213 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240216 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240119 Year of fee payment: 7 Ref country code: CH Payment date: 20240202 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240131 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220824 |